news aktuell GmbH

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation

7.12.2021 14:28:03 CET | news aktuell GmbH | Press release

Share
Darmstadt, 7 December 2021 – R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (“CTDA”). R-Biopharm will now work to resume the sale of the product in the UK.

RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.

Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“

 Press contact:

Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com 
https://r-biopharm.com/news-press

R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany

Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de 

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI19.11.2026 11:00:00 CET | Press release

Aachen, Germany, November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, start-ups, and research institutions at FEV’s headquarters in Aachen, Germany, on November 25 and 26. The event will focus on the latest technological developments, specific fields of application, and the prerequisites for the widespread adoption of advanced robotics.

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release

Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”

Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release

Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye